Tenet Health (THC)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-10-29
$270.57+0.77%
Close 2026-10-29 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-10-29
Research Workspace
Put THC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 5% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 8%.
View QualityManagement screens strong on capital allocation, earnings delivery, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskHealthy across the board
THC’s case rests on disciplined operations and improving margins, supported by strong recent financial performance. Revenue growth accelerated from 2.8% in Q1 to 6.8% in Q2, then eased to 6.5% in Q3. Q3 earnings beat consensus, and Tenet raised guidance. THC trades at 12× P/E versus a 23× peer median; expectations look modest versus our view. The specific risk is a guidance reversal after the recent increase. Our model puts the next-quarter miss probability near 19%. Peer multiples imply a price about 44% above where it trades; our read remains intact, this read is provisional.
Trailing returns as of 2026-10-29. THC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 23 analysts currently covering THC (as of Oct 2026).
Based on 14 Wall Street analysts offering 12-month price targets for THC in the last 4 months.
Continue this research
Compare THC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| THC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Facilities — fair value, gap to price, and forward P/E.
Compare the value case
Put THC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive strong revenue growth and organic/inorganic expansion
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $270.57
The last 12 months of price, then the range of analyst 12-month targets from today’s $270.57.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
2026 EBITDA forecast supports growth, though Conifer transition items temper quality.
Advances: Drive strong revenue growth and organic/inorganic expansion
Quarterly earnings call provides management updates on growth and operating priorities.
Advances: Drive strong revenue growth and organic/inorganic expansion
Earnings beat supports performance; share decline is a market reaction.
Advances: Drive strong revenue growth and organic/inorganic expansion
Raised guidance alongside an earnings beat supports growth expectations.
Advances: Grow ambulatory and hospital businesses
Faster hospital margin improvement would support the hospital business and operating execution.
Generate free cash flow and maintain capital discipline
Debt refinancing manages maturities but does not itself demonstrate deleveraging or cash generation.
All-time high indicates strong market confidence.
Raised guidance suggests positive outlook.
